Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Vicks Vaporub
030800000BDBQA0
|
Proprietary compound preparation BNF 0308000 | Other aromatic inhalation preparations | Respiratory System | No data available |
|
Vicks Vaposyrup for Chesty Coughs 66.67mg/5ml oral solution
0309020G0BEACAR
|
Vicks (Cough) | Guaifenesin | Respiratory System | No data available |
|
Vicks Vaposyrup for Tickly Coughs oral solution
030902000BECMA0
|
Proprietary compound preparation BNF 0309020 | Other expectorantand demulcent cough preparations | Respiratory System | No data available |
|
Vicryl Rapide suture 3gauge 90cm length with 35mm Tapercut half circle needle
20110000447
|
Vicryl Rapide suture 3gauge 90cm length with 35mm Tapercut half circle needle | Surgical Sutures | Dressings | No data available |
|
Vicryl suture 1.5gauge 75cm length with 19mm curved cutting P needle
20110000455
|
Vicryl suture 1.5gauge 75cm length with 19mm curved cutting P needle | Surgical Sutures | Dressings | No data available |
|
Vicryl suture 1gauge 45cm length with 16mm curved cutting P needle
20110000454
|
Vicryl suture 1gauge 45cm length with 16mm curved cutting P needle | Surgical Sutures | Dressings | No data available |
|
Vicryl suture 2gauge 45cm length with 26mm curved reverse cutting P needle
20110000456
|
Vicryl suture 2gauge 45cm length with 26mm curved reverse cutting P needle | Surgical Sutures | Dressings | No data available |
|
Victrelis 200mg capsules
0503032A0BBAAAA
|
Victrelis | Boceprevir | Infections | No data available |
|
Vidaza 100mg powder for suspension for injection vials
0801030ACBBAAAA
|
Vidaza | Azacitidine | Malignant Disease and Immunosuppression | No data available |
|
Videx 150mg chewable dispersible tablets
0503010N0BBADAD
|
Videx | Didanosine | Infections | No data available |
|
Videx 200mg chewable dispersible tablets
0503010N0BBAEAE
|
Videx | Didanosine | Infections | No data available |
|
Videx 25mg chewable dispersible tablets
0503010N0BBACAC
|
Videx | Didanosine | Infections | No data available |
|
Videx EC 125mg capsules
0503010N0BBAFAF
|
Videx | Didanosine | Infections | No data available |
|
Videx EC 200mg capsules
0503010N0BBAGAG
|
Videx | Didanosine | Infections | No data available |
|
Videx EC 250mg capsules
0503010N0BBAHAH
|
Videx | Didanosine | Infections | No data available |
|
Videx EC 400mg capsules
0503010N0BBAIAI
|
Videx | Didanosine | Infections | No data available |
|
Viekirax 12.5mg/75mg/50mg tablets
0503032G0BBAAAA
|
Viekirax | Paritaprevir/ritonavir/ombitasvir | Infections | No data available |
|
ViePax 37.5mg tablets
0403040W0BIACAA
|
Viepax | Venlafaxine | Central Nervous System | No data available |
|
Vigabatrin 100mg/5ml oral solution
0408010X0AAAUAU
|
Vigabatrin | Vigabatrin | Central Nervous System | No data available |
|
Vigabatrin 100mg/ml oral solution sugar free
0408010X0AABNBN
|
Vigabatrin | Vigabatrin | Central Nervous System | No data available |
|
Vigabatrin 350mg/5ml oral solution
0408010X0AABJBJ
|
Vigabatrin | Vigabatrin | Central Nervous System | No data available |
|
Vigabatrin 500mg/5ml oral solution
0408010X0AAAYAY
|
Vigabatrin | Vigabatrin | Central Nervous System | No data available |
|
Vigabatrin 700mg/5ml oral solution
0408010X0AABKBK
|
Vigabatrin | Vigabatrin | Central Nervous System | No data available |
|
Vigam Liquid 10g/200ml solution for infusion vials
1405010A0BLAFAC
|
Vigam | Normal immunoglobulin (Gamma globulin) | Immunological Products and Vaccines | No data available |
|
Vigam Liquid 2.5g/50ml solution for infusion vials
1405010A0BLAGAL
|
Vigam | Normal immunoglobulin (Gamma globulin) | Immunological Products and Vaccines | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.